Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors.
Clinical proteomics
colorectal cancer
immunohistochemistry
immunology
inflammatory response
label-free quantification
molecular biology
Journal
Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
30
05
2020
revised:
29
06
2020
pubmed:
10
7
2020
medline:
2
7
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
Using a simple, environment friendly proteome extraction (TOP), we were able to optimize the analysis of clinical samples. Using our TOP method we analyzed a clinical cohort of microsatellite stable (MSS) and unstable (MSI-H) colorectal carcinoma (CRC). We identified a tumor cell specific, STAT1-centered, immune signature expressed by the MSI-H tumor cells. We then showed that long, but not short, exposure to Interferon-γ induces a similar signature
Identifiants
pubmed: 32641473
pii: S1535-9476(20)35108-2
doi: 10.1074/mcp.RA120.002152
pmc: PMC8015011
pii:
doi:
Substances chimiques
Proteome
0
STAT1 Transcription Factor
0
STAT3 Transcription Factor
0
Formaldehyde
1HG84L3525
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1619-1631Informations de copyright
© 2020 Vainer et al.
Déclaration de conflit d'intérêts
Conflict of interest—The authors have declared a conflict of interest. E.D.V.- None; J.K.-A.- None; G.Z.- None; Y.L.- None; G.W.V.- reports grants, personal fees, nonfinancial support, and fees for travel and lecture from MSD, Roche, Pfizer, Abbvie, Takeda, BMS, Bayer and AstraZeneca are reported, none of them is directly related to this work.
Références
J Vis Exp. 2013 Sep 02;(79):
pubmed: 24022122
Eur J Cancer. 2017 Oct;84:290-303
pubmed: 28846956
Cancer Immunol Immunother. 2013 Jan;62(1):27-37
pubmed: 22729559
Mol Cell Biol. 1999 Jan;19(1):431-40
pubmed: 9858567
Immunity. 1998 Feb;8(2):157-66
pubmed: 9491997
Cytokine Growth Factor Rev. 2016 Jun;29:71-81
pubmed: 27053489
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1548-55
pubmed: 25773877
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Exp Med. 1992 Aug 1;176(2):327-37
pubmed: 1380059
Eur J Hum Genet. 2008 Oct;16(10):1235-9
pubmed: 18414508
Cytokine Growth Factor Rev. 2011 Aug;22(4):211-9
pubmed: 21752694
J Biol Chem. 2017 May 5;292(18):7285-7294
pubmed: 28289098
Cancer Immunol Res. 2019 Aug;7(8):1230-1236
pubmed: 31217164
Arch Pathol Lab Med. 2010 Jun;134(6):907-22
pubmed: 20524868
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Curr Treat Options Oncol. 2018 Aug 20;19(10):48
pubmed: 30128712
J Clin Immunol. 2015 Oct;35(7):615-23
pubmed: 26280891
Sci Rep. 2019 Aug 12;9(1):11697
pubmed: 31406210
Crit Rev Oncol Hematol. 2017 Feb;110:106-116
pubmed: 28109400
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Immunol Rev. 2000 Dec;178:129-37
pubmed: 11213797
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9373-8
pubmed: 19478064
J Clin Invest. 2007 Nov;117(11):3383-92
pubmed: 17932562
Cancer Cell. 2006 Jul;10(1):77-87
pubmed: 16843267
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
J Proteome Res. 2014 Dec 5;13(12):6187-95
pubmed: 25349961
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Fam Cancer. 2009;8(3):231-9
pubmed: 19165625
Crit Rev Oncol Hematol. 2017 Aug;116:38-57
pubmed: 28693799
Cancer Cell. 2009 Feb 3;15(2):103-13
pubmed: 19185845
J Proteome Res. 2011 Jul 1;10(7):3040-9
pubmed: 21526778
Expert Rev Proteomics. 2019 Jun;16(6):513-520
pubmed: 31094245
Cell. 1996 Feb 9;84(3):331-4
pubmed: 8608586
Neoplasia. 2007 Apr;9(4):279-91
pubmed: 17460772
Mol Cell Proteomics. 2014 Dec;13(12):3698-708
pubmed: 25360005
J Proteome Res. 2015 Jun 5;14(6):2707-13
pubmed: 25873244
Cell Signal. 2007 Mar;19(3):454-65
pubmed: 17085014
Front Immunol. 2019 Jun 26;10:1448
pubmed: 31293595
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Br J Cancer. 2013 Jul 9;109(1):138-46
pubmed: 23756862
Gastroenterology. 2013 Jul;145(1):63-78
pubmed: 23583733
Gastroenterology. 2010 Mar;138(3):1003-11.e1-5
pubmed: 19962983
PLoS One. 2011 Jan 31;6(1):e16353
pubmed: 21305021
Cancer Biomark. 2006;2(1-2):37-49
pubmed: 17192058
J Proteome Res. 2015 Sep 4;14(9):4005-18
pubmed: 26245529
Neoplasia. 2005 Jun;7(6):545-55
pubmed: 16036105
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
PLoS One. 2020 Apr 10;15(4):e0229252
pubmed: 32275681
Nature. 2014 Sep 18;513(7518):382-7
pubmed: 25043054
Proteomics Clin Appl. 2013 Apr;7(3-4):264-72
pubmed: 23339100
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Mol Cell. 2013 Feb 21;49(4):583-90
pubmed: 23438854
J Proteome Res. 2010 Jul 2;9(7):3688-700
pubmed: 20469934
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Biosci Trends. 2017 Mar 22;11(1):1-8
pubmed: 28154246
Int J Cancer. 2010 Aug 15;127(4):889-98
pubmed: 20013806
Clin Colorectal Cancer. 2016 Dec;15(4):285-291
pubmed: 27553906
Gut. 2010 Jul;59(7):926-33
pubmed: 20581241